3 categories of SARCoV2 testing - Infographic

Spacers and Valved Holding Chambers—The Risk of Switching to Different Chambers

REVIEW AND FEATURE ARTICLE

VOLUME 8, ISSUE 5, P1569-1573, MAY 01, 2020

Federico Lavorini, MD, PhD Celeste Barreto, MD, Job F.M. van Boven, PhD, Will Carroll, MD, Joy Conway, PhD, Richard W. Costello, MD, Birthe Hellqvist Dahl, PhD, Richard P.N. Dekhuijzen, MD, Stephen Holmes, MD, Mark Levy, MD, Mathieu Molimard, MD, PhD, Nicholas Roche, MD, PhD, Miguel Román-Rodriguez, MD, Nicola Scichilone, MD, Jane Scullion, MSc, Omar S. Usmani, MD, PhD

Abstract

Spacers are pressurized metered-dose inhaler (pMDI) accessory devices developed to reduce problems of poor inhaler technique with pMDIs. Spacers that feature a 1-way inspiratory valve are termed valved holding chambers (VHCs);

Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response

• EBioMedicine
• v.50; 2019 Dec
• PMC6921329

EBioMedicine. 2019 Dec; 50: 421–432.

Published online 2019 Nov 28. doi: 10.1016/j.ebiom.2019.11.006

PMCID: PMC6921329

PMID: 31786130

Julia Eckl-Dorna,a Milena Weber,b Victoria Stanek,a Birgit Linhart,b Robin Ristl,c Eva E. Waltl,a Sergio Villazala-Merino,a Andrea Hummel,a Margarete Focke-Tejkl,b Renate Froeschel,d Angela Neubauer,e Rainer Henning,e Thomas Perkmann,d Rudolf Valenta,b,f,g,⁎ and Verena Niederbergera

Associated Data

Supplementary Materials

Abstract

Background

BM32, a grass pollen allergy vaccine containing four recombinant fusion proteins

Application of probiotics in adjuvant treatment of infant allergic rhinitis

RESEARCH ARTICLE: STUDY PROTOCOL CLINICAL TRIAL
A randomized controlled study

Cao, Xueqiu MDa,b; Zhong, Ping MDa; Li, Gang MDa; Zhu, Jiao MDa; Zheng, Yun PhDa,∗Author Information
Medicine: May 2020 - Volume 99 - Issue 18 - p e20095
doi: 10.1097/MD.0000000000020095

• OPEN

Abstract
Background:
Several studies have suggested that intestinal flora may play an important role in allergic diseases. The purpose of this study was to investigate the effect of probiotics of Bifidobacterium triplex on the symptoms of allergic rhinitis (AR).

Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs

• Review
• Open Access
• 
  

Clinical and Translational Allergy

• O. Pfaar, 
• R. Gerth van Wijk, 
• L. Klimek, 
• J. Bousquet & 
• P. S. Creticos 

Clinical and Translational Allergy volume 10, Article number: 11 (2020) 

• details

Abstract

Allergen immunotherapy (AIT) is the only treatment option available for allergic patients with disease-modifying intention. Both efficacy and safety has been demonstrated for multiple trials in children, adolescents and adults. Though regulatory requirements for marketing authorization have been clearly outlined and an increasing number of high quality trials has been initiated, multiple concepts and details in study design may be further elaborated, harmonized and improved.

Prognostic factors for ARDS: clinical, physiological and atypical immunodeficiency

• BMC Pulmonary Medicine
• Research article
• Open Access
• 
  

• Min Song, 
• Yijie Liu, 
• Zhiwen Lu, 
• Hong Luo, 
• Hong Peng & 
• Ping Chen 

BMC Pulmonary Medicine volume 20, Article number: 102 (2020) 

• details

Abstract

Background

Relationships between the lymphocyte/neutrophil ratio and age,
APACHE II score, SOFA score, and PaO2/FiO2 ratio in ARDS patients

Risk factors affecting the prognosis of acute respiratory distress syndrome (ARDS) in adults were investigated. The aim was to identify new predictors for ARDS patient prognosis, including those with clinical, pathophysiological, and atypical immunodeficiency.

Methods

ARDS patients were retrospectively included. The patients were grouped and analysed according to different oxygenation index grades and prognosis, and factors influencing prognosis and survival were examined. Adolescent patients, patients with typical immunodeficiency and patients who died within 24 h after being diagnosed with ARDS were excluded. The predictive value for mortality was determined by Cox proportional hazard analysis.

Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis

Original Investigation

A Systematic Review and Network Meta-analysis

Aaron M. Drucker, MD^1,2; Alexandra G. Ellis, PhD³; Michal Bohdanowicz, MD¹; Soudeh Mashayekhi, MBBS⁴; Zenas Z. N. Yiu, PhD⁵; Bram Rochwerg, MD^6,7; Sonya Di Giorgio, MA⁸; Bernd W. M. Arents⁹; Tim Burton¹⁰; Phyllis I. Spuls, PhD¹¹; Denise Küster, MPH¹²; Doreen Siegels, BSc¹²; Jochen Schmitt, MD¹²; Carsten Flohr, PhD¹³

JAMA Dermatol. Published online April 22, 2020. doi:10.1001/jamadermatol.2020.0796

Key Points

Network Graphs of Studies Included in the Analysis of
Atopic Dermatitis Treatment Between 8 and 16 Weeks

Question  What is the relative effectiveness of systemic treatments for patients with atopic dermatitis?

Findings  This network meta-analysis of 39 randomized clinical trials including 6360 patients found that dupilumab and cyclosporine were similarly effective for adult patients with atopic dermatitis for up to 16 weeks of treatment and were more effective than methotrexate and azathioprine.

Meaning  Cyclosporine and dupilumab may have better short-term effectiveness than methotrexate and azathioprine for patients with atopic dermatitis; this analysis will be updated to add evidence as new medications are approved.

Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitis

Thomas Proctor, 

Elodie Morrough, 

Otto Fenske, 

Sarah Allatt, 

Stephen M. Hughes, 

Vibha Sharma & 

Peter D. Arkwright 

Clinical and Translational Allergy volume 10, Article number: 10 (2020) 

Abstract

Background

Pollen and house dust mite (HDM) subcutaneous immunotherapy (SLIT) and pollen subcutaneous immunotherapy (SCIT) are effective therapies for children with allergic rhinoconjunctivitis (AR). There are no previous direct comparative studies investigating quality of life (QoL) of all three immunotherapy regimes. The aim of this study was to compare QoL and safety in children receiving these immunotherapies for AR.